@article{ATM10780,
author = {Engelbert Bain Luchuo and Clovis Nkoke},
title = {A new look at human immunodeficiency virus infection and stroke in Sub-Saharan Africa},
journal = {Annals of Translational Medicine},
volume = {4},
number = {12},
year = {2016},
keywords = {},
abstract = {Stroke and human immunodeficiency virus (HIV) infection are major causes of morbidity and mortality in Sub-Saharan Africa (SSA), with disease burdens being amongst the highest worldwide. HIV infection has emerged as an important risk factor for stroke. The remarkable development in the treatment of HIV infection which occurred in recent decades has allowed the survival of a large number of patients. This therapeutic success which allows patients to live longer has facilitated the emergence of a new population of adults with increased risk for cardiovascular disease including stroke due to aging, the direct effects of HIV infection and combined anti-retroviral therapy (cART). Preventive strategies to decrease the burden of stroke amongst this specific patient population remain understudied in this region of the world. Lack of early diagnosis (CT scans) and poor record keeping make appreciation of the burden difficult. There is indisputable evidence that early diagnosis and early placement on cART therapy reduce HIV associated morbidity and mortality in this region of the world. However, the emergence of a new population of patients at risk for developing stroke (HIV patients) who fortunately live longer deserves a keener attention. Long term effects of cART regimens on cardiovascular and metabolic profiles remain uncertain, and specific cohort studies to properly ascertain its consequences are needed. The evidence and specific guidelines with regards to anti-platelet therapies and statin use, though potentially beneficial, in this patient sub group remains scarce. African specific cohort studies including HIV positive patients in our opinion should constitute a top research priority, to properly ascertain the potential roles of anti-platelet therapies and statins with regards to primary and secondary prevention of stroke, as well as long term effects of cART on their cardiovascular and metabolic profiles.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10780}
}